164 related articles for article (PubMed ID: 35258698)
1. Association of androgen excess and bone mineral density in women with classical congenital adrenal hyperplasia with 21-hydroxylase deficiency.
Lee DH; Kong SH; Jang HN; Ahn CH; Lim SG; Lee YA; Kim SW; Kim JH
Arch Osteoporos; 2022 Mar; 17(1):45. PubMed ID: 35258698
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density and fractures in congenital adrenal hyperplasia: Findings from the dsd-LIFE study.
Riehl G; Reisch N; Roehle R; Claahsen van der Grinten H; Falhammar H; Quinkler M
Clin Endocrinol (Oxf); 2020 Apr; 92(4):284-294. PubMed ID: 31886890
[TBL] [Abstract][Full Text] [Related]
3. Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency.
Auer MK; Paizoni L; Hofbauer LC; Rauner M; Chen Y; Schmidt H; Huebner A; Bidlingmaier M; Reisch N
J Steroid Biochem Mol Biol; 2020 Nov; 204():105734. PubMed ID: 32784048
[TBL] [Abstract][Full Text] [Related]
4. Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
El-Maouche D; Collier S; Prasad M; Reynolds JC; Merke DP
Clin Endocrinol (Oxf); 2015 Mar; 82(3):330-7. PubMed ID: 24862755
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-term glucocorticoid therapy on bone mineral density of the patients with congenital adrenal hyperplasia.
Ünal S; Alikaşifoğlu A; Özön A; Gönç N; Kandemir N
Turk J Pediatr; 2020; 62(3):359-366. PubMed ID: 32558409
[TBL] [Abstract][Full Text] [Related]
6. Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Ceccato F; Barbot M; Albiger N; Zilio M; De Toni P; Luisetto G; Zaninotto M; Greggio NA; Boscaro M; Scaroni C; Camozzi V
Eur J Endocrinol; 2016 Aug; 175(2):101-6. PubMed ID: 27185866
[TBL] [Abstract][Full Text] [Related]
7. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1996 Nov; 45(5):535-41. PubMed ID: 8977749
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density and body composition in prepubertal and adolescent patients with the classical form of 21-hydroxylase deficiency.
Sahakitrungruang T; Wacharasindhu S; Supornsilchai V; Srivuthana S; Kingpetch K
J Med Assoc Thai; 2008 May; 91(5):705-10. PubMed ID: 18672636
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency.
Elnecave RH; Kopacek C; Rigatto M; Keller Brenner J; Sisson de Castro JA
J Pediatr Endocrinol Metab; 2008 Dec; 21(12):1155-62. PubMed ID: 19189689
[TBL] [Abstract][Full Text] [Related]
10. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia.
King JA; Wisniewski AB; Bankowski BJ; Carson KA; Zacur HA; Migeon CJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):865-9. PubMed ID: 16278269
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density and body composition in children with congenital adrenal hyperplasia.
Halper A; Sanchez B; Hodges JS; Kelly AS; Dengel D; Nathan BM; Petryk A; Sarafoglou K
Clin Endocrinol (Oxf); 2018 Jun; 88(6):813-819. PubMed ID: 29460378
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia.
Ganesh R; Suresh N; Janakiraman L; Ravikumar K
Indian J Pediatr; 2016 Feb; 83(2):126-30. PubMed ID: 26223873
[TBL] [Abstract][Full Text] [Related]
13. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.
Chakhtoura Z; Bachelot A; Samara-Boustani D; Ruiz JC; Donadille B; Dulon J; Christin-Maître S; Bouvattier C; Raux-Demay MC; Bouchard P; Carel JC; Leger J; Kuttenn F; Polak M; Touraine P;
Eur J Endocrinol; 2008 Jun; 158(6):879-87. PubMed ID: 18390993
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.
Koetz KR; Ventz M; Diederich S; Quinkler M
J Clin Endocrinol Metab; 2012 Jan; 97(1):85-92. PubMed ID: 21994966
[TBL] [Abstract][Full Text] [Related]
15. Real-world impact of glucocorticoid replacement therapy on bone mineral density: retrospective experience of a large single-center CAH cohort spanning 24 years.
Iervolino LL; Ferraz-de-Souza B; Martin RM; Costa FC; Miranda MC; Mendonça BB; Bachega TS
Osteoporos Int; 2020 May; 31(5):905-912. PubMed ID: 31897546
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Bachelot A; Plu-Bureau G; Thibaud E; Laborde K; Pinto G; Samara D; Nihoul-Fékété C; Kuttenn F; Polak M; Touraine P
Horm Res; 2007; 67(6):268-76. PubMed ID: 17170529
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia.
Flokas ME; Wakim P; Kollender S; Sinaii N; Merke DP
J Clin Endocrinol Metab; 2024 Jan; 109(2):498-504. PubMed ID: 37643900
[TBL] [Abstract][Full Text] [Related]
18. The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia.
Cetinkaya S; Kara C
J Pediatr Endocrinol Metab; 2011; 24(5-6):265-9. PubMed ID: 21823521
[TBL] [Abstract][Full Text] [Related]
19. Bone density in young patients with congenital adrenal hyperplasia.
Mora S; Saggion F; Russo G; Weber G; Bellini A; Prinster C; Chiumello G
Bone; 1996 Apr; 18(4):337-40. PubMed ID: 8726391
[TBL] [Abstract][Full Text] [Related]
20. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency.
Falhammar H; Filipsson H; Holmdahl G; Janson PO; Nordenskjöld A; Hagenfeldt K; Thorén M
J Clin Endocrinol Metab; 2007 Dec; 92(12):4643-9. PubMed ID: 17878254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
